ARTICLE | Company News
Korean company ABL out-licenses antibody programs to U.S.
July 13, 2018 7:32 PM UTC
ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea.
ABL will receive $4.3 million up front and be eligible for $550 million in research, regulatory and sales milestones, plus royalties...